Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms
Autore:
Lemmens, P; Brecher, M; Van Baelen, B;
Indirizzi:
Janssen Res Fdn, B-2340 Beerse, Belgium Janssen Res Fdn Beerse Belgium B-2340 en Res Fdn, B-2340 Beerse, Belgium Janssen Res Fdn, Titusville, NJ USA Janssen Res Fdn Titusville NJ USAJanssen Res Fdn, Titusville, NJ USA
Titolo Testata:
ACTA PSYCHIATRICA SCANDINAVICA
fascicolo: 3, volume: 99, anno: 1999,
pagine: 160 - 170
SICI:
0001-690X(199903)99:3<160:ACAODS>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC-SCHIZOPHRENIC PATIENTS; TARDIVE-DYSKINESIA; RECEPTOR OCCUPANCY; PARALLEL-GROUP; HALOPERIDOL; MULTICENTER; RITANSERIN; CLOZAPINE; TRIALS; SCALE;
Keywords:
risperidone; haloperidol; schizophrenia; extrapyramidal symptoms; double-blind studies; tardive dyskinesia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Lemmens, P Janssen Res Fdn, Turnhoutseweg 30, B-2340 Beerse, Belgium Janssen Res Fdn Turnhoutseweg 30 Beerse Belgium B-2340 Belgium
Citazione:
P. Lemmens et al., "A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms", ACT PSYC SC, 99(3), 1999, pp. 160-170

Abstract

Combined data from double-blind risperidone studies were used to analyse the severity of extrapyramidal symptoms (EPS) associated with treatment in patients with chronic schizophrenia. Factors associated with maximum EPS severity were increasing risperidone dose (less than or equal to 8 mg/day was similar to placebo), lower baseline EPS scores, and longer duration of psychotic symptoms, particularly in older patients. EPS severity was significantly greater in patients receiving haloperidol or other antipsychotics than in those receiving risperidone (4 to 8 mg/day) or placebo. Antiparkinsonianmedications were required by significantly fewer patients treated with risperidone (4 to 8 mg/day) than by patients treated with haloperidol or otherantipsychotics. Combined efficacy data showed that 4 to 8 mg/day was also the most efficacious dose range; there was no increase in efficacy with doses over 4 mg/day. Based on these data and post-marketing experience, 4 mg/day is an appropriate initial target dose for most patients with schizophrenia. Higher doses may be appropriate for patients with chronic illness, and lower doses may be appropriate for patients with a first psychotic episode or for elderly patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 13:38:03